Rapt Therapeutics initiates prestIgE Phase 2b trial

RAPT Therapeutics (RAPT) announced that it has initiated the randomized, double-blind, placebo-controlled prestIgE Phase 2b clinical trial of ozureprubart in IgE-mediated food allergy. The study will involve approximately 30 sites in the U.S., Canada and Australia. “Food allergies are a large and growing problem for millions of patients worldwide,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT. “Initiating this trial is a significant milestone that reflects our strong execution, the validity of the early preclinical and clinical data generated by our partner, Jeyou, in China and our mission to provide patients with an improved anti-IgE therapy. We look forward to working with leading food allergists in the U.S., Canada and Australia to advance development of ozureprubart.”